<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT942-1322</title>
	</head>
	<body>
		<main>
			<p>940624 FT  24 JUN 94 / UK Company News: Glaxo signs migraine deal Glaxo, Europe's biggest drug company, has signed another deal in a string of collaborations with biotechnology companies. The company has bought most of the worldwide marketing rights to migraine treatments developed by Spectra Biomedical, a California group. The terms of the deal were not revealed beyond a three year agreement for research payments and that Glaxo would pay royalties to Spectra on product sales. Glaxo is seeking to develop a successor to its current migraine treatment, Imigran, which is one of its fastest growing products. The tie-up with Spectra takes to 12 the number of biotechnology collaborations established by Glaxo. It is the first in migraine. Spectra's approach is to try to determine the genetic basis for migraine. This is the first collaboration for Spectra, an unquoted company started a year ago by Mr Stephen Peroutka, formerly head of neuroscience at Genentech, the Californian biotechnology company which is 60 per cent-owned by Roche, the Swiss drug company Mr Peroutka said the number of staff was likely to double to 20 over the next 12 months.</p>
		</main>
</body></html>
            